Skip to main content
MedPathMedPath Home
Clinical Trials/DRKS00003454
DRKS00003454
Recruiting
Not Applicable

Combined diffusion tensor imaging (DTI, global fiber tracking and voxel based morphometry (VBM) in patients with idiopathic or atypical Parkinson syndrome

eurologische Universitätsklinikum Freiburg0 sites200 target enrollmentJanuary 11, 2012
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsG20G23Parkinson diseaseOther degenerative diseases of basal ganglia

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
G20
Sponsor
eurologische Universitätsklinikum Freiburg
Enrollment
200
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 11, 2012
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
eurologische Universitätsklinikum Freiburg

Eligibility Criteria

Inclusion Criteria

  • •Patients with parkinson's disease, multiple system atrophy, cortico\-basal degeneration, progressive supranuclear palsy or dementia with lewy bodies who are willing to participate at any state of the disease. Controls will be without neurological disease, matched for age.

Exclusion Criteria

  • •Contraindications against MRI as huge tatoos, implants as pace makers, impulse generators etc.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
The Pixel heterogeneity index: a new terminology for risk assessment of thromboembolismThrombus in the left atrial appendixThrombusembolismstrokeriskcerebral
TCTR20211021001/A10
Active, not recruiting
Not Applicable
MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED STUDY ON THE THERAPEUTIC EFFICACY AND SAFETY OF BECLOMETHASONE DIPROPIONATE SUSPENSION FOR INHALATION 800 micrograms TWICE DAILY VS PLACEBO ADDED TO ANTIBIOTIC THERAPY IN PATIENTS WITH ACUTE RHINOSINUSITISAcute rhinosinusitisMedDRA version: 14.1Level: LLTClassification code 10052106Term: RhinosinusitisSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2011-001459-35-ITCHIESI
Recruiting
Phase 1
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic DermatitisAtopic Dermatitis EczemaTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
CTIS2022-501476-25-00Eli Lilly & Co.291
Recruiting
Phase 3
JORTC-PAL16
JPRN-jRCTs051190097Matsuoka Hiromichi160
Completed
Not Applicable
A MULTICENTRIC, DOUBLE-BLIND, COMPARATIVE, RANDOMIZED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF MK-0991 COMPARED WITH (ANFOTERICIN B) LIPOSOMAL INJECTABLE AS EMPIRICAL THERAPY IN PATIENTS WITH PERSISTENT FEVER AND NEUTROPENIA-R509 Fever, unspecifiedFever, unspecifiedR509
PER-020-00MERCK SHARP & DOHME PERU S.R.L.,